Stryker Co. (NYSE:SYK) Shares Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH lifted its position in shares of Stryker Co. (NYSE:SYK) by 14.8% in the fourth quarter, Holdings Channel reports. The firm owned 5,476 shares of the medical technology company’s stock after purchasing an additional 707 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Stryker were worth $1,972,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Dunhill Financial LLC grew its holdings in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the period. Centennial Bank AR boosted its holdings in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after acquiring an additional 48 shares during the period. Darwin Wealth Management LLC purchased a new position in Stryker in the 3rd quarter worth approximately $36,000. HBW Advisory Services LLC purchased a new position in Stryker in the 3rd quarter worth approximately $42,000. Finally, Hara Capital LLC purchased a new position in Stryker in the 3rd quarter worth approximately $42,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Citigroup upped their price target on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. UBS Group upped their price target on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity Group increased their target price on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird increased their target price on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Price Performance

Shares of NYSE SYK opened at $393.79 on Friday. Stryker Co. has a 1-year low of $307.23 and a 1-year high of $398.20. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The business’s fifty day moving average price is $375.82 and its two-hundred day moving average price is $360.16. The firm has a market capitalization of $150.12 billion, a PE ratio of 42.21, a P/E/G ratio of 2.72 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period last year, the company earned $2.46 earnings per share. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. On average, research analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.85%. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Insiders Place Their Bets

In other news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.90% of the stock is owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.